Pharma News, 2020

Months after the FDA pointed out manufacturing concerns at a Cipla plant in India—including workers using dirty disposable socks that may have caused contamination—the drugmaker said it was ready ...

A new study published in a BMJ journal has found that inadequate screening in heart failure has cost the NHS an avoidable £21.

Pfizer has revealed that its investigational Janus kinase 1 (JAK1) inhibitor, abrocitinib, has met its co-primary efficacy endpoints in a Phase III moderate to severe atopic dermatitis trial.

Oxford Biomedica has signed a Licence and Clinical Supply Agreement (LSA) with Bristol-Myers Squibb’s Juno Theraputics, granting the latter a non-exclusive license to the LentiVector platfor...

MSD has revealed new topline efficacy results from two ongoing pivotal Phase III trials, evaluating gefapixant (MK-7264) in refractory or unexplained chronic cough.

Biotech giant Regeneron said it aims to have doses of a potential drug for COVID-19 ready to start human clinical trials by early summer.

Geneva, 16 March 2020 – Bristol-Myers Squibb (BMS) has announced that the marketing authorisations for Daklinza® (daclatasvir) will be withdrawn or will be allowed to lapse in count...

Following government issued advice to avoid all non-essential travel and contact in the UK, various pharmaceutical companies are stepping up to offer vaccine candidates, funding and more.

Novo Nordisk has paused the Phase III explorer and explorer trials for haemophilia drug concizumab, due to non-fatal thrombotic events, the company says.

Patients with polyps have a higher risk of colorectal cancer, and those with sessile serrated polyps, tubulovillous adenomas, and villous adenomas had a higher colorectal cancer mortality.

A group of neuroscience and neurotechnology researchers have conducted extensive research and developed a new brain imaging technology in two EU projects led by Aalto University.

Adaptive Phage Therapeutics (APT) said that the U.